定位高端，又是专业户外圈备受追捧的顶级品牌，对滔搏而言，这是一次双赢的合作。"Norr na贯穿于产品研发、生产工艺和消费者服务的长期主义品 牌理念，与滔搏的长期主义价值观高度契合。双方的合作旨在聚焦长线，携手共同深挖户外领域的可持续发展潜力。"上述相关知情人士对北京商报记 者说道。 获独家运营权 5月7日，北京商报记者获悉，运动零售运营商滔搏宣布与专业户外品牌Norr na达成合作，滔搏成为Norr na在中国市场的独家运营合作伙伴。对于本就 困在单一代理模式中的滔搏而言，此次合作意味着其在高端户外赛道拿到了颇有分量的入场券。但入场是一回事，能否立足又是另一回事，曾经因销 售不及预期退场的Norr na，此番卷土重来能否帮滔搏解困还有待观察。 据了解，通过此次合作，滔搏将负责Norr na品牌在中国市场的品牌宣传、市场推广、渠道销售、消费者运营等全链路运营工作。 有接近滔搏的相关知情人士对北京商报记者透露，接下来，滔搏将对Norr na品牌进行线上线下（300959）一系列规划。 "渠道规划遵循'全域经营+精准触达'的核心逻辑，通过线上线下协同，构建覆盖专业运动圈层的立体化销售网络。在线下，开设Norr n ...

根据公告，TLX591是一款全球创新、携带治疗性放射性核素的单克隆抗体产品，拟用于治疗既往接受 过ARPI治疗进展的前列腺特异性膜抗原（PSMA）阳性mCRPC患者。 前列腺癌是老年男性泌尿生殖系统常见的恶性肿瘤之一，其发病率和死亡率分别位列全球男性恶性肿瘤 发病和死亡谱的第二位和第五位，在中国男性中分别居第六位和第七位。 本报讯 （记者张敏）5月7日晚间，港股上市公司远大医药集团有限公司（以下简称"远大医药"）发布 的公告显示，公司用于治疗前列腺癌的全球创新放射性核素偶联药物（RDC）TLX591（177Lu- HuJ591）加入国际多中心Ⅲ期临床试验（IND）申请已获得国家药监局正式受理。 本次TLX591获受理的是一项前瞻性、随机、对照、开放标签、国际多中心的Ⅲ期临床试验，拟在中 国、美国、澳大利亚、新西兰等全球多个国家入组500余名患者，旨在评估TLX591联合标准治疗与仅接 受标准治疗相比，在既往接受过雄激素受体通路抑制剂（ARPI）治疗进展的转移性去势抵抗性前列腺 癌患者（mCRPC）中的疗效和安全性。 然而，目前我国前列腺癌治疗传统放疗因累积辐射剂量高，易导致肠道损伤、尿失禁等并发症，严重影 响 ...

印度政府：印度内政部长主持了安全审查会议，与巴基斯坦和尼泊尔接壤的边境邦的副州长和首席部长 举行了会谈。 ...

Core Insights - JD Health and China National Pharmaceutical Group have signed a strategic cooperation agreement to enhance the accessibility of quality medical resources and promote health technology [1][2] - The partnership aims to launch innovative pharmaceutical products, including the first domestically approved tolvaptan patch and a sodium loxoprofen gel patch, through JD Health's online channels [1][2] Group 1: Strategic Partnership - JD Health and China National Pharmaceutical Group will collaborate in disease knowledge dissemination and new product launches [1] - The partnership is expected to leverage JD Health's online platform to improve public access to healthcare services [1][2] Group 2: Product Launches - JD Health will exclusively distribute the 2mg tolvaptan patch online, which is designed to alleviate symptoms of bronchial asthma and other obstructive airway diseases [1] - Another product, sodium loxoprofen gel patch, is the first in China to complete phase III clinical trials and is aimed at treating inflammation and pain from osteoarthritis and muscle injuries [1] Group 3: Market Trends - JD Health is positioned as the leading online health consumption platform, with e-commerce channels projected to account for 12.9% of the pharmaceutical retail market by 2024 [2] - The company employs a comprehensive "B2C + O2O + offline store" model to integrate supply chain, logistics, and medical resources effectively [2] Group 4: Future Collaboration - The partnership will expand to cover various disease areas, including oncology, rheumatology, and cardiovascular health, utilizing JD Health's internet hospital resources [2] - Both companies aim to transform authoritative medical knowledge into accessible content for the public, enhancing health education and chronic disease management [2]

Group 1 - The core point of the news is that Mengniu Dairy has been actively repurchasing its shares, with a total of 423,000 shares repurchased this year, amounting to HKD 7,410.33 million [2][3] - On May 7, the company repurchased 300,000 shares at a price range of HKD 19.260 to HKD 19.660, totaling HKD 582.53 million, while the stock closed at HKD 19.260, down 3.60% for the day [2] - Since May 6, the company has conducted share buybacks for two consecutive days, repurchasing a total of 320,000 shares, with a cumulative buyback amount of HKD 622.33 million, during which the stock price fell by 4.42% [2] Group 2 - The detailed buyback history shows that the highest repurchase price this year was HKD 19.900 on May 6, and the lowest was HKD 14.980 on January 16 [3] - The buyback activity includes multiple transactions, with the largest single buyback of 800,000 shares on April 7, amounting to HKD 1,428.82 million [3] - The company has engaged in 18 buyback transactions this year, indicating a consistent strategy to support its stock price [3]

证券时报·数据宝统计，上海石油化工股份在港交所公告显示，5月7日以每股1.180港元至1.200港元的价 格回购315.60万股，回购金额达378.53万港元。该股当日收盘价1.200港元，上涨1.69%，全天成交额 3028.29万港元。 自4月24日以来公司已连续8日进行回购，合计回购1884.40万股，累计回购金额2199.13万港元。 其间该 股累计下跌0.83%。 今年以来该股累计进行30次回购，合计回购5982.00万股，累计回购金额7009.61万港元。（数据宝） 上海石油化工股份回购明细 | 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.05.07 | 315.60 | 1.200 | 1.180 | 378.53 | | 2025.05.06 | 260.00 | 1.180 | 1.170 | 306.20 | | 2025.05.02 | 67.40 | 1.170 | 1.160 | 78.49 | | 2025.04.30 | 204.60 | 1. ...

Core Viewpoint - The company, He Yu-B, has been actively repurchasing its shares in the Hong Kong stock market, indicating a strategy to support its stock price amidst recent declines [1] Share Buyback Summary - On May 7, the company repurchased 600,000 shares at prices ranging from HKD 7.310 to HKD 7.860, totaling HKD 4.4488 million [1] - The stock closed at HKD 7.400 on the same day, reflecting a decline of 5.37%, with a total trading volume of HKD 41.6738 million [1] - Since April 25, the company has conducted buybacks for seven consecutive days, acquiring a total of 1.8 million shares for a cumulative amount of HKD 13.7038 million, during which the stock price fell by 5.97% [1] - Year-to-date, the company has executed 20 buybacks, totaling 5.398 million shares and an aggregate repurchase amount of HKD 39.5059 million [1] Detailed Buyback Data - The buyback details include various dates, number of shares repurchased, highest and lowest prices, and total amounts spent, showcasing a consistent effort to stabilize the stock price [1]

Core Viewpoint - China Biotechnology Services (08037) announced that its indirect non-wholly owned subsidiary, Shanghai Longyao Biotechnology Co., Ltd., will present the Phase I clinical trial results of LY007 cell injection at two major international conferences in 2025, highlighting its potential to fill the treatment gap in CD20 CAR-T therapy [1] Group 1: Efficacy and Safety - LY007 features a unique OX40 co-stimulation signal design that significantly enhances T cell expansion and anti-tumor activity. Phase I clinical trial data shows that 92% of 12 patients with relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma experienced tumor reduction or disappearance, with a best complete response rate (BCRR) of 75%. One patient who failed CD19 CAR-T treatment achieved complete remission without severe cytokine release syndrome or neurotoxicity [2] Group 2: Differentiated Indication Strategy - LY007 offers a new treatment option for patients who failed CD19 CAR-T therapy or are CD19-negative relapsed. The CAR-T cells peaked at 46% to 80% of CD3+ T cells in patients. Shanghai Longyao plans to further promote international multicenter clinical research for LY007 at the International Conference on Malignant Lymphoma and the European Hematology Association meeting, exploring collaborations with European and American institutions. The company has laid out 14 global patents to support product commercialization and expansion into solid tumor indications. Over the past year, the Phase I clinical research results of LY007 have been presented at major global oncology and hematology conferences, indicating recognition and attention in the global academic field [3]

Core Insights - The article highlights the significant growth and global expansion of the Chinese toy brand Pop Mart, particularly in the context of a sluggish global consumer market [4][5][12] - Pop Mart's innovative approach to its IP (Intellectual Property) and product offerings has allowed it to thrive, with a notable increase in revenue and market presence [5][12][22] Group 1: Financial Performance - Pop Mart's revenue for the first quarter of the 2025 fiscal year surged by 165% year-on-year, reaching approximately 170 million [4] - The company's market capitalization exceeded 230 billion HKD, surpassing that of French luxury giant Kering, which stands at 189.8 billion HKD [4] - In 2024, Pop Mart reported that four of its IPs generated over 1 billion in revenue, with 13 IPs exceeding 100 million [5] Group 2: Global Expansion - As of 2024, Pop Mart has opened 147 retail stores outside mainland China, with 37 located in the United States, marking an increase of 11 stores since the beginning of the year [12] - Revenue from overseas markets accounted for 38.9% of the total revenue, reflecting a staggering year-on-year growth of 375.2% [12][22] - The company's overseas business revenue increased by 440% in the first three quarters of 2024, with income from international markets exceeding 30% of total revenue [22] Group 3: Consumer Engagement and Market Strategy - Pop Mart has successfully transformed the excitement of "blind box" purchases into a social value centered around emotions and sharing, distinguishing itself from traditional toy markets [15][19] - The brand's target audience has expanded beyond young women to include a broader demographic, with its characters resonating with various age groups [17][21] - Pop Mart's products are increasingly viewed as universal gifts, appealing to consumers looking for presents for friends and family, thus broadening its market appeal [21] Group 4: Cultural Impact and Brand Identity - Pop Mart's global strategy emphasizes cultural recognition and emotional value, aiming to resonate with local consumers rather than just targeting the Asian demographic [24] - The brand's success illustrates a new model of cultural export, where it translates local elements into universally relatable emotions, creating globally appealing consumer products [22][24] - The company is positioned to redefine contemporary toy consumption by integrating emotional narratives and community engagement into its brand identity [26]

一面是财务数据高歌猛进，一面是股权被接连减持，泡泡玛特（09992.HK）又一次走入舆论中心。 记者查阅泡泡玛特股权信息发现，加上最近的一次，近期发生的三次减持分别为405万股、400万股、 386万股，总计1191万股，占泡泡玛特股份比例约为0.9%，套现约22.64亿港元。关于此次连续减持，记 者联系了泡泡玛特方面，但截至发稿，泡泡玛特官方并未置评。 在前述公众号文章中，屠铮表示："从天使阶段第一次投资到最终出售，陪伴公司（泡泡玛特）整整14 年，First in Last out（先进后出），过程跌宕起伏，波澜壮阔；坚守至今，万分不舍，心存感激。" 据了解，作为专注于新消费与TMT（科技、媒体和通信）核心技术的中早期风投机构，蜂巧资本由屠 铮、常欣于2018年创立，核心团队均来自一线创投机构，擅长挖掘Z世代与女性生活方式赛道的潜力企 业，曾培育出蕉下、内外、库客音乐等明星项目。 在对泡泡玛特的投资过程中，屠铮展现出超前的行业预判力。十几年前，屠铮以启赋资本合伙人身份首 次接触仅有3家门店的泡泡玛特，敏锐捕捉到潮玩市场的情感消费潜力，按照8000万元估值完成700万元 独家投资。 公开信息显示，4月30日 ...